Does biologic therapy reduce coronary inflammation assessed by perivascular FAI in patients with moderate to severe psoriasis?
Biologic therapy in psoriasis patients is associated with reduced coronary inflammation, suggesting perivascular FAI via CCTA could track responses to interventions for coronary artery disease.
In this study, biologic therapy for moderate to severe psoriasis was associated with reduced coronary inflammation assessed by perivascular FAI. This finding suggests that perivascular FAI measured by CCTA may be used to track response to interventions for coronary artery disease.
Elnabawi et al. (2019) studied this question.